Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $719.9 million, a modest decline of 2% year-over-year, primarily due to headwinds in legacy products [5][6] - Operating cash flow totaled $156.1 million, demonstrating the resilience of the company's business model [6][13] - Net income for Q4 2025 was $24.4 million, or $0.51 per share, down from $38 million, or $0.74 per share in the prior year [13] Business Line Data and Key Metrics Changes - BAQSIMI generated $185.4 million in revenue for the full year, up 12% year-over-year, driven by higher U.S. unit volumes [5][10] - Primatene MIST sales rose 7% to $108.7 million, supported by strong consumer demand [5] - Glucagon sales declined 45% to $14.1 million due to increased competition and market shifts [11] - Epinephrine sales decreased 9% to $17.1 million, partially offset by increased demand for pre-filled syringes [11] Market Data and Key Metrics Changes - The company expects mid-single-digit unit growth for BAQSIMI in the U.S. in 2026, offset by a planned reduction in international volume [14][26] - The Atrovent market, previously experiencing a decline, is expected to stabilize due to pricing considerations and payer preferences [29][30] Company Strategy and Development Direction - The company aims to transition towards a portfolio anchored in high-value proprietary and biosimilar assets, with a focus on complex generics and innovative therapies [4][18] - Significant investments are planned for the expansion of the U.S. manufacturing facility in Rancho Cucamonga, which will quadruple production capacity [8][16] - The launch of Ipratropium Bromide is expected to be a significant near-term growth driver [4][15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining operational discipline and prioritizing long-term investments despite margin pressures [6][15] - The company anticipates lower gross margins in 2026 due to pricing pressures on glucagon and epinephrine, alongside rising input costs [15][36] - Management expressed optimism about the potential for significant long-term value creation through focused execution and innovation [18] Other Important Information - The company has over $300 million in cash and short-term investments, which will be utilized for stock buybacks and potential business development opportunities [16][36] - The company is exploring business development opportunities in endocrinology, oncology, ophthalmology, and immunology [22] Q&A Session Summary Question: Development path for AMP-110 and business development priorities - The company has not yet engaged the FDA regarding AMP-110 but is internally discussing the program [21] - Business development will focus on areas where the company has or plans to have a presence, including endocrinology and oncology [22] Question: BAQSIMI expectations for 2026 and international sales - The company expects mid-single-digit growth in U.S. unit sales, with a decline in international sales anticipated in the second half of the year [26][27] Question: Gross margins and buyback plans - BAQSIMI growth is expected to help gross margins, but declines in glucagon and epinephrine will offset some of this [36] - The company plans to use a portion of its cash for buybacks, with $75 million being the high end of the range for the previous year [36] Question: Competition for Primatene MIST and lifecycle management - The company does not anticipate significant competition for Primatene MIST despite the patent expiration, citing strong brand equity [41][42] - The company is developing a new formulation of Primatene MIST and has secured one patent [42] Question: Updates on Nanjing Anji in-licensed assets - The company is in the preclinical stage for these assets and is optimistic about their potential [46][47]